JP2003512324A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003512324A5 JP2003512324A5 JP2001531383A JP2001531383A JP2003512324A5 JP 2003512324 A5 JP2003512324 A5 JP 2003512324A5 JP 2001531383 A JP2001531383 A JP 2001531383A JP 2001531383 A JP2001531383 A JP 2001531383A JP 2003512324 A5 JP2003512324 A5 JP 2003512324A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- ethyl
- glaucoma
- formula
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 9
- 208000010412 Glaucoma Diseases 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 208000030533 eye disease Diseases 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 210000001328 optic nerve Anatomy 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 206010067013 Normal tension glaucoma Diseases 0.000 description 3
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 3
- 201000002978 low tension glaucoma Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical compound C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99120678 | 1999-10-19 | ||
| EP99120678.0 | 1999-10-19 | ||
| PCT/EP2000/010234 WO2001028553A1 (en) | 1999-10-19 | 2000-10-17 | Rivastigmine for the treatment of ocular disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003512324A JP2003512324A (ja) | 2003-04-02 |
| JP2003512324A5 true JP2003512324A5 (enExample) | 2007-12-06 |
Family
ID=8239225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001531383A Pending JP2003512324A (ja) | 1999-10-19 | 2000-10-17 | 眼疾患の処置のためのリバスチグミン |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6534541B1 (enExample) |
| EP (1) | EP1225890B1 (enExample) |
| JP (1) | JP2003512324A (enExample) |
| AR (1) | AR026062A1 (enExample) |
| AT (1) | ATE285764T1 (enExample) |
| AU (1) | AU766001B2 (enExample) |
| CA (1) | CA2384690C (enExample) |
| DE (1) | DE60017174T2 (enExample) |
| DK (1) | DK1225890T3 (enExample) |
| ES (1) | ES2234708T3 (enExample) |
| NZ (1) | NZ518164A (enExample) |
| PT (1) | PT1225890E (enExample) |
| WO (1) | WO2001028553A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2237163T3 (es) | 1998-10-01 | 2005-07-16 | Novartis Ag | Nuevas formulaciones orales de revastigmina de liberacion controlada. |
| US9993558B2 (en) | 2004-10-01 | 2018-06-12 | Ramscor, Inc. | Sustained release eye drop formulations |
| US8541413B2 (en) * | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
| WO2009022345A1 (en) * | 2007-08-14 | 2009-02-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Phenyl carbamates for the treatment of multiple sclerosis |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
| CN107417574B (zh) * | 2017-03-21 | 2019-12-03 | 浙江省医学科学院 | 2,4-双取代苯乙酮化合物及其旋光异构体、药学上可接受的盐及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL74497A (en) | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
| HU201906B (en) * | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
| US4900748A (en) | 1988-03-04 | 1990-02-13 | The United States Of America As Represented By The Department Of Health And Human Services | Carbamates related to (-)-physostigmine as cholinergic agents |
| JP3708957B2 (ja) | 1991-09-26 | 2005-10-19 | アメリカ合衆国 | （−）−エゼロリン、（−）−ｎ１−ノルエゼロリンおよび（−）−ｎ１−ベンジルノルエゼロリンの置換フェンゼリンおよびフェニルカルバミン酸塩：特異的アセチルコリンエステラーゼ阻害薬としての使用 |
| ES2206449T3 (es) | 1991-09-26 | 2004-05-16 | The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services | Inhibidores de colinesterasas, composiciones farmaceuticas y sus usos. |
| AU1138097A (en) * | 1995-12-22 | 1997-07-17 | Alcon Laboratories, Inc. | Combinations of prostaglandins and miotics for lowering intraocular pressure |
-
2000
- 2000-10-11 US US09/686,025 patent/US6534541B1/en not_active Expired - Fee Related
- 2000-10-17 ES ES00992430T patent/ES2234708T3/es not_active Expired - Lifetime
- 2000-10-17 PT PT00992430T patent/PT1225890E/pt unknown
- 2000-10-17 EP EP00992430A patent/EP1225890B1/en not_active Expired - Lifetime
- 2000-10-17 AU AU28349/01A patent/AU766001B2/en not_active Ceased
- 2000-10-17 JP JP2001531383A patent/JP2003512324A/ja active Pending
- 2000-10-17 DE DE60017174T patent/DE60017174T2/de not_active Expired - Lifetime
- 2000-10-17 AR ARP000105450A patent/AR026062A1/es unknown
- 2000-10-17 AT AT00992430T patent/ATE285764T1/de active
- 2000-10-17 WO PCT/EP2000/010234 patent/WO2001028553A1/en not_active Ceased
- 2000-10-17 NZ NZ518164A patent/NZ518164A/en not_active IP Right Cessation
- 2000-10-17 DK DK00992430T patent/DK1225890T3/da active
- 2000-10-17 CA CA2384690A patent/CA2384690C/en not_active Expired - Fee Related
-
2003
- 2003-01-23 US US10/349,718 patent/US6835748B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4154237B2 (ja) | 異痛症および他の種々のタイプの慢性疼痛または幻肢痛を治療するための化合物のペプチドクラスの新規使用 | |
| US8093262B2 (en) | Use of huperzine for disorders | |
| ES2435403T3 (es) | Tratamiento de trastornos del sueño y vigilia | |
| US11590107B2 (en) | Methods for treating neurological disorders with α1A-AR partial agonists | |
| US20200375958A1 (en) | Membrane active molecules | |
| CA2528160A1 (en) | Use of 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine for neuronal regeneration and functional recovery | |
| TW201240662A (en) | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases | |
| JP6903571B2 (ja) | スミス‐マゲニス症候群を治療するためのタシメルテオン | |
| JP4867123B2 (ja) | 神経因性疼痛治療剤および神経因性疼痛のモデル動物 | |
| US20020132793A1 (en) | Use of methylphenidate compounds to enhance memory | |
| CN101484004A (zh) | 新型大麻素及使用方法 | |
| JP2003512324A5 (enExample) | ||
| JPWO2001014383A1 (ja) | 神経因性疼痛治療剤および神経因性疼痛のモデル動物 | |
| JP4043236B2 (ja) | １−環状アミノ−アルキルシクロヘキサン化合物、その薬学的調合物及びこれを鎮痙薬として使用する方法 | |
| KR950032171A (ko) | 옥소피리디닐퀴녹살린 유도체 | |
| EP3615023B1 (en) | Lipoyl-glu-ala for the treatment of neurodegenerative damage caused by traumatic brain injury | |
| US20060004050A1 (en) | Compositions and methods for the prevention or treatment of pain and other nervous system disorders | |
| CN111518028B (zh) | 一种一氧化氮供体型ripasudil衍生物及其制备方法和用途 | |
| US6534541B1 (en) | Treatment of ocular disorders | |
| US20190175555A1 (en) | Use Of Carbamate Compound For Preventing Or Treating Trigeminal Neuralgia | |
| JP2003530350A (ja) | 外傷性脳損傷及びその他のニューロン障害治療用医薬 | |
| ES2231495T3 (es) | Compuestos derivados de felbamato para tratar el dolor neuropatico. | |
| US20250115596A1 (en) | Esters of 8-methyl-8-azabicyclo[3.2.1] octan-3-yl 3-hydroxy-2-phenylpropanoate | |
| WO2024006841A2 (en) | Compositions for weight loss and cancer treatment | |
| EP4463156A1 (en) | Topical naltrexone as a treatment for dry eye |